Calcium-protein Co-ingestion and Gut Hormones

The Acute Effects of Calcium-protein Co-ingestion on Gut Hormone Secretion

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03370497

Enrollment

Registered

2017-12-12

Start date

2017-10-01

Completion date

2018-02-28

Last updated

2018-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Diabetes

Brief summary

Gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (T2D). Rodent evidence suggests that calcium may potentiate the effects of protein ingestion on gut hormone secretion. Evidence in humans however, is lacking. This study aims to assess whether the addition of calcium to protein ingestion augments postprandial gut hormone availability in humans.

Interventions

DIETARY_SUPPLEMENTMilk Mineral Supplement

Milk Minerals containing 1000 mg calcium

DIETARY_SUPPLEMENTWhey Protein Hydrolysate

50 g whey protein hydrolysate

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Randomised, double-blind crossover

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy men and women age between 18-65 yrs. * Able to consume provided supplement. * Weight stable for the past 3 month (no change within 3%)

Exclusion criteria

* Any previous or current metabolic, cardio-pulmonary or musculoskeletal disease * Not between the ages of 18-65 years * A body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared) * Taking medications that may influence your metabolism * Plans to change your lifestyle (diet and/or physical activity) during the study period * Not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions. * Current smoker

Design outcomes

Primary

Measure	Time frame	Description
Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).	120 min	Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).

Secondary

Measure	Time frame	Description
Postprandial plasma GIP area under the curve (mmol/L x 120 min)	120 min	Postprandial plasma GIP area under the curve (mmol/L x 120 min)
Postprandial plasma PYY area under the curve (mmol/L x 120 min)	120 min	Postprandial plasma PYY area under the curve (mmol/L x 120 min)
Subjective ratings of appetite (au)	120 min	Subjective ratings of appetite (au)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026